XOMA Royalty (XOMA) to Release Earnings on Monday

XOMA Royalty (NASDAQ:XOMA) is anticipated to release its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect XOMA Royalty to post earnings of ($0.04) per share and revenue of $11.13 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Monday, March 16, 2026 at 9:30 AM ET.

XOMA Royalty Stock Performance

Shares of XOMA stock opened at $25.98 on Monday. The company has a current ratio of 3.91, a quick ratio of 3.91 and a debt-to-equity ratio of 1.07. The firm has a fifty day simple moving average of $26.07 and a two-hundred day simple moving average of $30.83. XOMA Royalty has a 12 month low of $18.35 and a 12 month high of $39.92. The firm has a market capitalization of $321.63 million, a PE ratio of 35.11 and a beta of 0.86.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Zacks Research upgraded shares of XOMA Royalty from a “strong sell” rating to a “hold” rating in a report on Monday, February 9th. Stifel Nicolaus set a $50.00 price target on shares of XOMA Royalty in a research report on Friday, December 12th. TD Cowen raised shares of XOMA Royalty to a “hold” rating in a research report on Friday, February 13th. Wall Street Zen downgraded XOMA Royalty from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Finally, Leerink Partners reissued an “outperform” rating on shares of XOMA Royalty in a research note on Tuesday, February 24th. Three analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $61.60.

Hedge Funds Weigh In On XOMA Royalty

Hedge funds and other institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. increased its position in shares of XOMA Royalty by 3,436.4% during the third quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 756 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in XOMA Royalty by 203.1% in the second quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,523 shares during the last quarter. JPMorgan Chase & Co. boosted its position in XOMA Royalty by 13.9% in the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 543 shares during the last quarter. Raymond James Financial Inc. bought a new position in XOMA Royalty in the 2nd quarter valued at $116,000. Finally, BNP Paribas Financial Markets grew its stake in XOMA Royalty by 266.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,226 shares of the biotechnology company’s stock valued at $124,000 after purchasing an additional 2,346 shares during the period. Hedge funds and other institutional investors own 95.92% of the company’s stock.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.